(-0.10%) 5 303.00 points
(-0.06%) 40 119 points
(-0.14%) 18 479 points
(1.34%) $82.44
(-0.93%) $1.702
(0.77%) $2 229.70
(-0.35%) $24.67
(0.19%) $911.45
(0.38%) $0.927
(0.65%) $10.84
(0.15%) $0.792
(-0.16%) $92.30
Live Chart Being Loaded With Signals
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases...
Stats | |
---|---|
Today's Volume | 958 508 |
Average Volume | 2.13M |
Market Cap | 23.78B |
EPS | TWD0 ( 2024-03-11 ) |
Next earnings date | ( TWD0 ) 2024-05-08 |
Last Dividend | TWD0 ( N/A ) |
Next Dividend | TWD0 ( N/A ) |
P/E | -116.32 |
ATR14 | TWD0.0690 (0.08%) |
Volume Correlation
TaiMed Biologics Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
TaiMed Biologics Inc. Correlation - Currency/Commodity
TaiMed Biologics Inc. Financials
Annual | 2023 |
Revenue: | TWD491.78M |
Gross Profit: | TWD225.23M (45.80 %) |
EPS: | TWD-0.760 |
Q4 | 2023 |
Revenue: | TWD158.22M |
Gross Profit: | TWD69.11M (43.68 %) |
EPS: | TWD-0.240 |
Q3 | 2023 |
Revenue: | TWD157.55M |
Gross Profit: | TWD77.33M (49.08 %) |
EPS: | TWD-0.0229 |
Q2 | 2023 |
Revenue: | TWD104.24M |
Gross Profit: | TWD33.88M (32.50 %) |
EPS: | TWD-0.190 |
Financial Reports:
No articles found.
TaiMed Biologics Inc.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators